Allen Institute for Artificial Intelligence
supp.ai logo
supp.ai

Discover Supplement-Drug Interactions

Disclaimer: The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The tool is not a substitute for the care provided… (more)
Last Updated: 3 years ago

Possible Interaction: Dinoprostone and Sphingosine 1-Phosphate

Research Papers that Mention the Interaction

S1P significantly enhanced COX-2 expression and PGE2 secretion, and this was repressed by the selective COX-2 inhibitor celecoxib, the corticosteroid dexamethasone, or small interfering RNA (siRNA) knockdown of COX-2 expression.
American journal of respiratory cell and molecular biology  •  2016  |  View Paper
In the present study, our results demonstrated that treatment with S1P significantly induced COX-2, but not COX-1, expression and increased PGE2 production in human granulosa cells.
Cellular signalling  •  2016  |  View Paper
Sphingosine‐1‐phosphate S1P ) has been shown to regulate cyclooxygenase‐2 (COX‐2)/prostaglandin E2 ( PGE2 ) expression and IL‐6 secretion in various respiratory diseases.
Journal of cellular physiology  •  2015  |  View Paper
S1P dose-dependently inhibited IL-1β-induced NF-κB p65, cyclooxygenase (COX)-2, MMP-1, MMP-3, MMP-13 and MMP-14 mRNA expression in human chondrocytes and IL-1β-induced PGE2 synthesis and GAG degradation in human cartilage explants.
International journal of molecular medicine  •  2012  |  View Paper
ConclusionIt was suggested that the S1P-induced PGE2 was at least in part involved in the aggrecan-suppressing effect of S1P , seeing as COX inhibitors attenuated the effect.
BMC musculoskeletal disorders  •  2007  |  View Paper
S1P alone significantly enhanced COX-2 expression and PGE2 production.
Arthritis and rheumatism  •  2006  |  View Paper
Analysis of the mechanisms involved in growth inhibition revealed that S1P rapidly increased prostaglandin E2 production and in turn cAMP, two growth inhibitory messengers for hMF; C2-ceramide and sphingosine, which inhibited hMF proliferation, did not affect cAMP levels.
We conclude that S1P inhibits proliferation of hMF, probably via an intracellular mechanism, through early COX-2-dependent release of prostaglandin E2 and cAMP, and delayed COX-2 induction.
The Journal of Biological Chemistry  •  2000  |  View Paper
RsPP (2.5mg/kg) significantly inhibited the inflammatory peak of paw edema induced by histamine (44.0%), bradykinin (51.3%), or prostaglandin E2 (53.7%).
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie  •  2017  |  View Paper
S1P is able to cause increases in COX-2 and PGE2 levels in RAW cells.
Prostaglandins & other lipid mediators  •  2008  |  View Paper